Obesity biotech Alveus raises ~$160M Series A to advance MariTide‑like GLP‑1/GIPR drug and amylin pipeline

on

Alveus Therapeutics, a Philadelphia- and Copenhagen-based obesity and metabolic disease biotech, launched with a $159.8M (~$160M) Series A financing announced Jan. 8, 2026.245

The Series A was led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capital, Kurma Partners, Avego BioScience Capital, and other healthcare investors.2345

Lead asset ALV-100 is a bifunctional GIPR antagonist / GLP‑1 receptor agonist fusion protein, mechanistically similar to Amgen’s long‑acting GLP‑1/GIP dual‑target drug MariTide, and is being advanced into Phase 2 obesity trials.45

Alveus aims for more durable weight loss, less frequent dosing, improved tolerability, and better body‑composition (lean‑mass) outcomes versus current GLP‑1–based obesity drugs from Eli Lilly and Novo Nordisk.345

Nonhuman primate data for ALV‑100 suggest preservation of lean body mass and potentially fewer tolerability issues compared with existing GLP‑1 therapies.4

The company is also building a next‑generation amylin-based pipeline spanning injectable and oral modalities, designed for superior durability, tolerability, and metabolic outcomes.245

Its lead amylin candidate ALV‑200 is a highly selective amylin receptor 3 (AMYR3) peptide agonist that has reached the IND‑enabling stage; additional amylin programs include oral small molecules and multifunctional formats.245

Series A proceeds will primarily fund Phase 2 clinical development of ALV‑100 and IND filings for several early proprietary candidates, including the selective amylin peptide agonist ALV‑200.235

Alveus positions itself squarely in Amgen MariTide’s competitive landscape, targeting the same GLP‑1/GIP axis plus amylin, with the goal of setting a new standard of care in obesity and metabolic disease.345

The company is led by CEO Raj Kannan (former CEO of i‑Mab, Aerie Pharmaceuticals, and Chiasma) and backed by a management and scientific team with extensive obesity and metabolic drug development experience.23

Sources:

2. https://alveustx.com/news/alveus-therapeutics-launches-with-160-million-series-a-financing-to-advance-next-generation-therapies-for-obesity-and-metabolic-diseases/

3. https://www.fiercebiotech.com/biotech/equipped-150m-series-alveus-debuts-crowded-obesity-development-landscape

4. https://www.biopharmadive.com/news/alveus-obesity-biotech-startup-glp-gipr-amylin-financing/809148/

5. https://www.pharmaceutical-technology.com/news/alveus-debuts-in-obesity-arena-with-160m-series-a/